Last reviewed · How we verify
Quadrivalent Influenza Virus Split Vaccine
This vaccine stimulates the immune system to produce antibodies and cellular immunity against four strains of influenza virus.
This vaccine stimulates the immune system to produce antibodies and cellular immunity against four strains of influenza virus. Used for Prophylaxis of influenza caused by influenza A and B viruses.
At a glance
| Generic name | Quadrivalent Influenza Virus Split Vaccine |
|---|---|
| Sponsor | Shanghai Institute Of Biological Products |
| Drug class | Inactivated split influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The quadrivalent split vaccine contains inactivated viral antigens from two influenza A strains (H1N1 and H3N2) and two influenza B strains. When administered, these antigens trigger both humoral (antibody) and cell-mediated immune responses, enabling the body to recognize and neutralize circulating influenza viruses before infection occurs or to reduce disease severity if infection develops.
Approved indications
- Prophylaxis of influenza caused by influenza A and B viruses
Common side effects
- Injection site pain, erythema, or swelling
- Myalgia
- Headache
- Fever
- Fatigue
Key clinical trials
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months (PHASE3)
- High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients (PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults (PHASE1)
- Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older (PHASE3)
- Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children . (PHASE3)
- Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older (PHASE3)
- High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: